Biomedicine

Kythera Biopharmaceuticals Initiates Phase II Study of Its Adipolytic Agent for Reduction of Submental Fat

Published in Lab Business Week, September 16th, 2007

Kythera Biopharmaceuticals, Inc. ("Kythera") announced that it has initiated a Phase II study of its proprietary product, ATX-101, for the reduction of unwanted submental (under chin) fat. This is the first in a series of planned studies of ATX-101 in aesthetic applications aimed at proving the product's safety and effectiveness as a "liposculpting" agent.

This is also the first prospective, placebo-controlled, study on an adipolytic agent under an active registration program. The study is designed as part of a package aimed at achieving registration of ATX-101 as an approved prescription drug in the U.S., Europe and Asia. The Phase II multi-national, randomized,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2007-09-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry